HIV Diagnosis Market By Mode, By Test Type, By End-use : Global Opportunity Analysis and Industry Forecast, 2023-2032

List of Tables

The global HIV diagnosis market was valued at $1.9 billion in 2022, and is projected to reach $2.7 billion by 2032, growing at a CAGR of 3.9% from 2023 to 2032.

It is a procedure that determines if a person has contracted the Human Immunodeficiency Virus (HIV), a virus that leads to acquired immunodeficiency syndrome (AIDS). Several approaches and methodologies are used in HIV testing to establish whether an individual has HIV antibodies, antigens, or gene (RNA or DNA) in his blood volumes, saliva, and urine. Essentially, the focus of HIV testing is aimed at detecting infected persons very early, offering them relevant medical attention as well as preventing others from acquiring the infection.

Trends in HIV diagnosis exhibit a diverse landscape shaped by factors including geographical location, demographics, prevention measures, and healthcare accessibility. Notably, several high-income countries with robust prevention and treatment programs have witnessed a decline in new HIV diagnoses due to heightened awareness, widespread testing, improved treatment access, and preventive strategies such as Pre-exposure prophylaxis (PrEP). For instance, in 2022, according to Organization for Economic Cooperation and Development (OECD) in Asia-Pacific, the prevalence of HIV infection varied importantly, ranging from less than 0.1% of adults aged 15 to 49 in Bangladesh, Mongolia, New Zealand, and Sri Lanka to 1% of adults aged 15 to 49 in Thailand in 2020. Although HIV prevalence was low, the absolute number of people living with HIV was high at more than 2.2 million in reporting countries and territories in 2021, owing to Asia-Pacific's large population.

Although there have been advancements in the prevention and treatment of HIV, it is important to note that some specific populations such as men who have sexual intercourse with other men (MSM), transgender people, and racial minorities continue to report high rates of HIV diagnoses. These disparities underscore prevailing inequalities in care. At the same time, new HIV epidemics are emerging within certain populations or regions, owing to factors such as injecting drugs and difficulties in accessing healthcare services. Young people also remain vulnerable in certain areas such as sub-Saharan Africa as they lack adequate sex education and limited access to health care.

The HIV diagnosis market is segmented into mode, test type, end use, and region. By mode, the market is segregated into self-test and lab based. By test type the market is segregated into antibody/antigen test, viral load test/nucleic acid test, CD4 test, and test for early infant diagnosis. Antibody/antigen test is further segregated into HIV-1 screening tests, HIV-1 antibody confirmatory tests, and HIV-2 & Group Of diagnostic tests. By end use, the market is segregated into diagnostic laboratories, hospitals & clinics, and home settings. By region, the HIV diagnosis market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Major companies operating in this market include Abbott, Gilead Sciences, Inc., Merck & Co. Inc., Beckman Coulter, Inc., Mylan N.V., F. Hoffman-La Roche Ltd., Siemens Healthcare GmbH, QIAGEN, Bio-Rad Laboratories, Inc., and Hologic. Key players have adopted product launch and collaboration as their key strategy to improve the product portfolio of the testosterone replacement therapy market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv diagnosis market analysis from 2022 to 2032 to identify the prevailing hiv diagnosis market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hiv diagnosis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hiv diagnosis market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Market share analysis of players at global/region/country level
SWOT Analysis

Key Market Segments

By Mode

Self-test
Lab-based

By Test Type

Antibody/Antigen Test
- Type
- HIV-1 Screening Tests
- HIV-1 Antibody Confirmatory Tests
- HIV-2 and Group O Diagnostic Tests
Viral load test/Nucleic Acid Test
CD4 test
Test for Early Infant Diagnosis

By End-use

Diagnostic Laboratories
Hospitals and Clinics
Home Settings

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Abbott Laboratories
Gilead Sciences, Inc.
Merck & Co. Inc.
Danaher Corporation
Mylan N.V.
F Hoffman La Roche Ltd
Siemens Healthcare Private Limited
Qiagen NV.
Bio-Rad Laboratories, Inc.
Hologic Inc.

Product Code: A02480

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: HIV DIAGNOSIS MARKET, BY MODE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Self-test
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Lab-based
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: HIV DIAGNOSIS MARKET, BY TEST TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Antibody/Antigen Test
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.2.4. Antibody/Antigen Test HIV Diagnosis Market by Type
5.3. Viral load test/Nucleic Acid Test
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. CD4 test
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Test for Early Infant Diagnosis
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: HIV DIAGNOSIS MARKET, BY END-USE

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Diagnostic Laboratories
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Hospitals and Clinics
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Home Settings
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: HIV DIAGNOSIS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Mode
- 7.2.3. Market size and forecast, by Test Type
- 7.2.4. Market size and forecast, by End-use
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Mode
  - 7.2.5.1.2. Market size and forecast, by Test Type
  - 7.2.5.1.3. Market size and forecast, by End-use
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Mode
  - 7.2.5.2.2. Market size and forecast, by Test Type
  - 7.2.5.2.3. Market size and forecast, by End-use
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Mode
  - 7.2.5.3.2. Market size and forecast, by Test Type
  - 7.2.5.3.3. Market size and forecast, by End-use
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Mode
- 7.3.3. Market size and forecast, by Test Type
- 7.3.4. Market size and forecast, by End-use
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Mode
  - 7.3.5.1.2. Market size and forecast, by Test Type
  - 7.3.5.1.3. Market size and forecast, by End-use
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Mode
  - 7.3.5.2.2. Market size and forecast, by Test Type
  - 7.3.5.2.3. Market size and forecast, by End-use
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Mode
  - 7.3.5.3.2. Market size and forecast, by Test Type
  - 7.3.5.3.3. Market size and forecast, by End-use
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Mode
  - 7.3.5.4.2. Market size and forecast, by Test Type
  - 7.3.5.4.3. Market size and forecast, by End-use
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Mode
  - 7.3.5.5.2. Market size and forecast, by Test Type
  - 7.3.5.5.3. Market size and forecast, by End-use
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Mode
  - 7.3.5.6.2. Market size and forecast, by Test Type
  - 7.3.5.6.3. Market size and forecast, by End-use
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Mode
- 7.4.3. Market size and forecast, by Test Type
- 7.4.4. Market size and forecast, by End-use
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Mode
  - 7.4.5.1.2. Market size and forecast, by Test Type
  - 7.4.5.1.3. Market size and forecast, by End-use
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Mode
  - 7.4.5.2.2. Market size and forecast, by Test Type
  - 7.4.5.2.3. Market size and forecast, by End-use
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Market size and forecast, by Mode
  - 7.4.5.3.2. Market size and forecast, by Test Type
  - 7.4.5.3.3. Market size and forecast, by End-use
  - 7.4.5.4. India
  - 7.4.5.4.1. Market size and forecast, by Mode
  - 7.4.5.4.2. Market size and forecast, by Test Type
  - 7.4.5.4.3. Market size and forecast, by End-use
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Mode
  - 7.4.5.5.2. Market size and forecast, by Test Type
  - 7.4.5.5.3. Market size and forecast, by End-use
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Mode
  - 7.4.5.6.2. Market size and forecast, by Test Type
  - 7.4.5.6.3. Market size and forecast, by End-use
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Mode
- 7.5.3. Market size and forecast, by Test Type
- 7.5.4. Market size and forecast, by End-use
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Mode
  - 7.5.5.1.2. Market size and forecast, by Test Type
  - 7.5.5.1.3. Market size and forecast, by End-use
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Mode
  - 7.5.5.2.2. Market size and forecast, by Test Type
  - 7.5.5.2.3. Market size and forecast, by End-use
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Mode
  - 7.5.5.3.2. Market size and forecast, by Test Type
  - 7.5.5.3.3. Market size and forecast, by End-use
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Mode
  - 7.5.5.4.2. Market size and forecast, by Test Type
  - 7.5.5.4.3. Market size and forecast, by End-use

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Abbott Laboratories
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Gilead Sciences, Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Merck & Co. Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Danaher Corporation
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Mylan N.V.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. F Hoffman La Roche Ltd
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Siemens Healthcare Private Limited
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Qiagen NV.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Bio-Rad Laboratories, Inc.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Hologic Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments